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Abstract
Background—Toxoplasma gondii (T. gondii) is a neurotropic protozoan parasite that causes 
persistent infection in humans. A substantial literature suggests that schizophrenia is associated 
with increased seroprevalence of T. gondii, but a possible link of the parasite with mood disorders 
has not been as thoroughly investigated.
Methods—We examined the association of Toxoplasma-specific IgG results with mood disorder 
outcomes in 7440 respondents from the third National Health and Nutrition Survey (NHANES 
III), which is a nationally representative sample of the U.S. noninstitutionalized civilian 
population. Regression models were adjusted for numerous potential confounders including 
tobacco smoking and C-reactive protein levels.
Results—No statistically significant associations were found between T. gondii seroprevalence 
and a history of major depression (n=574; adjusted odds ratio, 0.8; 95% CI 0.5–1.2), severe major 
depression (n=515; adjusted odds ratio, 0.8; 95% CI, 0.6– 1.2), dysthymia (n=548; adjusted odds 
ratio, 1.1; 95% CI 0.7–1.8), or dysthymia with co-morbid major depression (n=242, adjusted odds 
ratio, 1.2; 95% CI 0.6–2.4), all p-values were >0.05, including analysis stratified by gender. 
However, there was a significant relationship between T. gondii seroprevalence and bipolar 
disorder type I for respondents in which both manic and major depression symptoms were 
reported (n=41; adjusted odds ratio, 2.4; 95% CI, 1.2–4.8; p<0.05).
Conclusions—In a population-based sample, T. gondii seroprevalence is not elevated in 
unipolar mood disorders but is higher in a subset of respondents with a history of bipolar disorder 
type 1.
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Introduction
Toxoplasma gondii (T. gondii) is a protozoan parasite that infects humans by exposure to the 
organism in contaminated soil, water, undercooked meat, or in cat feces (1). It has evolved a 
complex lifecycle to continue its existence, which includes unique mechanisms to evade 
immune-mediated destruction and modify host behavior (2, 3). T. gondii is neuroinvasive 
and causes a persistent brain infection in rodents (3, 4). T. gondii cysts are assumed to 
remain in the brains of infected humans for life, but this assumption is based on the 
permissibility of human neural cells and the common reactivation of latent T. gondii during 
immunosuppression, as well as incidental findings of T. gondii cysts in brain tissue on 
autopsy (2, 5, 6).
Studies in humans and rodents have yielded indirect evidence implicating T. gondii in 
neuropsychiatric disorders. T. gondii evolved to induce subtle behavioral dysfunction 
causing infected rodents to have reduced fear of cats, promoting the transmission of the 
parasite (3, 4, 7). Although infection of the human host is irrelevant to the life cycle of the 
parasite in modern times, there is no reason to think that the ability of T. gondii to influence 
neurotransmitter regulation and host behavior becomes disengaged upon infection of the 
human brain. Several neurotransmitters relevant to mood disorders and psychosis may be 
affected by T. gondii infection (4, 8). For example, there is evidence that infection with T. 
gondii can induce indoleamine 2,3-dioxygenase, which can then decrease serotonin and 
influence glutamatergic neurotransmission (4, 9). Studies in animal models suggest that T. 
gondii upregulates dopaminergic neurotransmission, and the T. gondii genome contains two 
genes that code for tyrosine hydroxylase, the rate-limiting enzyme for synthesis of dopamine 
(4, 10). Among psychiatric illnesses, T. gondii has been studied most extensively in 
schizophrenia, and a meta-analysis found the overall the odds of T. gondii seropositivity was 
2.73 times higher in schizophrenic patients than the general population (2).
The relationship of T. gondii infection and mood disorders is less clear. Two recent studies 
of T. gondii serology, which were focused on schizophrenia, also included individuals with 
major depressive disorder (MDD). These studies did not find a significant association 
between T. gondii seroprevalence and unipolar major depression. However, these were small 
case-control studies with 50 or fewer cases of MDD (11, 12). Another larger study (focused 
on suicide) examined T. gondii serology in 218 individuals classified as having major 
depression or bipolar disorder along with 39 healthy controls. While this study did not find a 
statistical association between T. gondii seropositivity and these mood disorders, the patients 
with mood disorders were a unique clinical sample with inclusion based on a prior suicide 
attempt or enrollment in a different study examining the relationship between depression 
and allergy (13). Thus, the results from this study may not be broadly applicable, though T. 
gondii antibody titers were higher in individuals who had attempted suicide versus those 
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without a history of suicide attempts. Another study examined T. gondii titers in inpatients 
being treated for depression, with the main analysis focused on 221 of these inpatients who 
were over age 45 years (9). While there was no significant difference in seroprevalence 
between the patients with depression and healthy controls, there were more individuals with 
high serointensity (i.e. high T. gondii antibody titers) in the major depression group 
compared to the control group.
Studies of T. gondii in bipolar disorder have also been inconclusive, in part because they 
have not clearly defined bipolar disorder and its subtypes, or they have collapsed multiple 
psychiatric illnesses into a single group. One large study using clinical samples from 
patients treated in a psychiatry department in China defined recent-onset affective disorders 
based on elevated scores on psychological tests of depression or mania (14). T. gondii 
seroprevalence did not differ between this affective disorders group and the control group. 
Another study of an inpatient population with various psychiatric disorders did not find 
evidence of heightened T. gondii seroprevalence in bipolar disorder or schizophrenia (15). 
However, this study mainly utilized patients with personality disorder co-morbidities. Other 
studies of T. gondii in affective psychosis have focused exclusively on prenatal or neonatal 
exposures (16–18).
Thus, the relationship between T. gondii exposure and major depression or bipolar disorder 
has not been studied in a population-based and racially diverse sample. A large sample is 
desirable because a number of potential confounder and mediator variables deserve 
consideration. For example, in addition to key demographic variables, several studies have 
shown an association between mood disorders and low-grade inflammation (19). In 
particular, major depression and bipolar mania are positively-associated with serum levels of 
C-reactive protein (CRP) (20–22). In the current study we examined the association between 
T. gondii exposure and several well-defined mood disorders in a sample of 7440 individuals 
age 15–39 years using the Third National Health and Nutrition Examination Survey 
(NHANES III). We controlled for demographic variables in addition to CRP and smoking.
Methods
To examine the relationship between prevalence of IgG antibodies to T. gondii and the 
diagnosis of selected mood disorders we used data from NHANES III, a cross-sectional 
survey conducted between 1988 and 1994 by the National Center for Health Statistics, 
Centers for Disease Control and Prevention. NHANES III was designed to obtain nationally 
representative statistics on health measures and conditions through household interviews, 
standardized physical examinations, and collection of biological specimens in mobile 
examination centers (23). NHANES III was based on a stratified, multistage, probability 
cluster design from which a sample representative of the civilian, noninstitutionalized U.S. 
population aged 2 months or older was drawn (23). Non-Hispanic Blacks, Mexican-
Americans, children 2 months through 5 years, and persons ≥ 60 years of age were sampled 
at higher rates than other persons to assure an adequate sample size for these groups. Degree 
of urbanization was dichotomized as metro and non-metro with metro areas defined as 
central counties or fringe counties of metro areas with a population of 1 million or more and 
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non-metro as all others. Detailed descriptions of the design of the survey and the sample 
have been described elsewhere (23).
Surplus sera were tested for the prevalence of IgG antibodies to T. gondii. During the 
physical examination the Diagnostic Interview Schedule (DIS) (24), a structured psychiatric 
interview schedule, was administered in a private room. The Diagnostic and Statistical 
Manual of Mental Disorders - Edition 3 DSM-III version of the DIS was used in NHANES 
III. The DIS was administered only to respondents who were age 15–39 at the time of the 
interview, which limited the analysis to this relatively young subgroup. These data yielded 
lifetime prevalence for the seven mood disorder outcomes of interest. Specifically, 
respondents were coded dichotomously for ever having met the criteria for each mood 
disorder diagnosis (severe major depression, major depression, dysthymia with and without 
history of major depression, bipolar disorder type I with and without both manic and 
depressive episodes, and atypical bipolar disorder (bipolar type II) using the NHANES III 
reference source book)(25).
For depression, the primary analysis focused on individuals meeting lifetime criteria for 
severe major depression without bereavement (coded as MQPDEP=3). The criteria for 
severity of depression in this group were seeking professional help or medication, or 
affirming that the symptoms of depression interfered a lot with the respondent’s life or 
activities. Additional analysis used a broader category that did not consider severity and 
included all eligible respondents with a lifetime history of major depression, including 
severe and non-severe subtypes without bereavement (MQPDEP=2 or 3). Dysthymia was 
classified as a broad category that included dysthymia with or without a history of major 
depression (MQPDYSTH= 2 or 3). Respondents were classified as having double 
depression if they met lifetime criteria for dysthymia and major depressive episode as well 
(MQPDYSTH= 3)(25)
For bipolar disorder, the main analysis focused on bipolar disorder type I in which 
respondents met severity and exclusion criteria for both a manic and a depressive episode 
(MQPBIPOL=2). In addition, a more inclusive group included respondents that met criteria 
for a manic episode but for whom a depressive episode diagnosis was coded as either absent 
or missing (MQPBIPOL=2 or 3). Atypical bipolar disorder (bipolar type II) was defined by 
hypomanic episodes in addition to major depression, and this diagnosis was only made in 
respondents who had not met criteria for a manic episode or bipolar I (MQPBIPII= 2 or 3)
(25).
Socio-demographic factors related to mood disorders and T. gondii seropositivity were also 
assessed. Age was grouped as 15–19, 20–29, and 30–39 years. Race/ethnicity was based on 
self-reported information and categorized as non-Hispanic White, non-Hispanic Black, or 
Mexican American. Those who did not self-select as non-Hispanic white, non-Hispanic 
black, or Mexican American were placed in the “other” racial/ethnic group, which is 
included in the calculations for the total population but not in the models because the 
sampling frame was not designed to create national estimates representative of this group. 
Poverty index was calculated by dividing the total family income by the U.S. poverty 
threshold, adjusted for family size and categorized as below poverty (<1.0) and at or above 
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poverty (>=1.0). Education was measured as the last year of schooling completed by the 
individual (for sample persons age 20–39 years) or the head of household (for sample 
persons age 15–19 years) and grouped into three levels (less than high school, high school 
completed, and some college or college graduate). Place of birth was coded as U.S. versus 
non-U.S. Smoking was assessed by questionnaire and coded as current smoker versus past 
or never smoked.
Laboratory testing
Surplus sera specimens were tested for T. gondii IgG antibodies using the Patelia Toxo-G 
immunoglobulin G enzyme immunoassay (Sanofi Diagnostics Pasteur, BioRad, Hercules, 
California), according to the manufacturer’s instructions. Prior to the study the Patelia Toxo-
G kit was evaluated by comparison with the Centers for Disease Control and Prevention’s 
Toxoplasma immunofluorescence assay-immunogloblin G test and Sabin-Feldman dye test 
(Dr. Jack Remington, Palo Alto, California) and found to have a sensitivity and specificity 
of 100% (1). For most analysis, T. gondii antibody titers were categorized as negative (< 6 
IU) or positive (>=6 IU)), according to the manufacturer’s instructions. We also performed a 
sub-analysis of serointensity that further distinguished between seropositive respondents 
with high Toxoplasma titers (>=240 IU) compared to intermediate titers (6-239 IU)(26).
In addition, C-reactive protein (CRP) levels were measured and used as a cofactor when 
examining the relationship between T. gondii infection and prevalence of a mood disorder. 
CRP levels were measured using a latex-enhanced Behring Nephelometer (26). The 
coefficient of variation for CRP throughout the period of data collection was 3.2% to 16.1% 
(26). Consistent with previous studies of depression in this cohort, CRP was dichotomized 
as undetectable (<2.2mg/L) versus elevated (>=2.2 mg/L)(20, 21).
Statistical analysis
Prevalence estimates were weighted to represent the total U.S. population and to account for 
oversampling and nonresponse to the household interview and physical examination (27, 
28). Statistical analyses were conducted with SUDAAN (version 10.0.1), a family of 
statistical procedures for analysis of data from complex sample surveys (Research Triangle 
Park, NC: Research Triangle Institute). Standard error estimates were calculated using the 
Taylor Series Linearization method. Ninety-five percent confidence limits were estimated by 
using the exact binomial method (29). Estimates with relative standard errors (RSEs) greater 
than or equal to 40 were not reported because they are considered highly unstable. 
Multivariate logistic regression was used to examine the association between T. gondii 
infection and prevalence of each mood disorder. Multiple models for each mood disorder 
outcome were examined (each included a variable for T. gondii infection): a univariate 
model with only T. gondii infection, a model adjusting for age, race/ethnicity and gender, 
and a fully adjusted model with all potential cofactors under consideration, including a 
variable for CRP level. Additional analysis explored the relationship between CRP and 
unipolar mood disorders in logistic models stratified by T. gondii seropositivity. A P-value 
of <0.05 from a Satterthwaite adjusted F-statistic was considered significant.
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Our sample consisted of individuals with complete data on all mood disorder diagnoses who 
were tested for T. gondii antibody. Specifically, 9473 individuals age 15–39 years were 
interviewed and 8773 (93% of those interviewed) were examined. Of the 8773 individuals 
examined, 8433 (96%) had complete mood disorder data, 7715 (88%) were tested for T. 
gondii antibodies, and 7440 (85% of those examined) had complete data for both. Although 
differences in response to completing both the T. gondii serologic testing and the DIS III 
varied significantly by levels of age, race/ethnicity, education, and foreign birth (p<0.05 
from a chi-square analysis) response varied by <=3% among levels of each of these 
variables except with respect to foreign birth (81% among those foreign born versus 86% 
among those U.S. born).
Results
Characteristics of the study population are shown in Table 1. All percentages reported are 
weighted; the actual number of respondents is reported only to indicate sample size in each 
subgroup. Of the 7440 respondents included in this study, 1211 were seropositive for 
Toxoplasma gondii with a weighted percent of 14.5 (95% CI, 13.0–16.0).
As shown in table 2, there was no statistically significant association between T. gondii 
seroprevalence and severe major depression (unadjusted OR, 0.8; 95% CI, 0.5 –1.1). In 
addition, there was no statistically significant association between T. gondii serology and a 
history of major depression inclusive of severe and non-severe subtypes (unadjusted OR, 
0.7; 95% CI, 0.5–1.1) as well as dysthymia (unadjusted OR, 1.3; 95% CI, 0.8 –1.9) or 
dysthymia combined with major depression (unadjusted OR, 1.3; 95% CI, 0.7–2.3). Since 
each of these logistic models in this population-based analysis included some respondents in 
the comparison group with a positive history of one or more mood disorders, which might 
bias our results toward the null, additional analysis were performed that limited the 
comparison group to only those individuals who never met criteria for any mood disorder. 
These results also indicated no association between T. gondii seropositivity and any 
combination of major depression or dysthymia (P>0.05, data not shown). Based on the 
emerging concept that the robustness of the antibody response (i.e. serointensity or T. gondii 
titer) rather than seroprevalence is an important factor linking T. gondii with psychiatric 
illnesses (9, 13) additional analyses were performed categorizing T. gondii serology results 
as a three level variable, < 6 IU (negative), 6-239 IU (intermediate titer), >=240 (high titer). 
For major depression, and dysthymia with major depression, the relative standard errors 
were too high for reliable estimates (RSE > 40%). For dysthymia there was no significant 
relationship with T. gondii serointensity (P>0.10, data not shown).
Several potential confounding variables were considered in adjusted models (Table 2). 
Adjustment for age, race/ethnicity, and gender resulted in similar ORs as the unadjusted 
findings. There was also no statistically-significant relationship between T. gondii 
seropositivity and any of these unipolar mood disorders in the full model, which controlled 
for age, race/ethnicity, gender, poverty level, education level, foreign birth, smoking and 
CRP level (Table 2). Elimination of CRP from these models did not reveal any significant 
associations (P>0.05). However, since these mood disorders were more common in women, 
and prior studies have shown an association between CRP and depression only in men, the 
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fully adjusted models were rerun stratified by gender. Again, no significant association 
between T. gondii seropositivity and any of these mood disorders was found (p>0.05, data 
not shown). As expected, in men but not women these models revealed a significant 
association between high CRP and each of these unipolar mood disorders (P<0.05, data not 
shown). The largest effect of CRP was observed in men with a history of dysthymia and 
depression, “double depression” (OR 5.1, 95% CI 1.9–13.6, p<0.01).
Because T. gondii infection could be contributing to some of the reported differences 
between men and women in the correlation between elevated CRP and mood disorder risk, 
we further explored the relationship between CRP and these mood disorders in logistic 
models stratified by T. gondii seropositivity and adjusted for age, race/ethnicity, poverty 
level, education, foreign birth, and smoking. In women, there was still no significant 
association between CRP and any of these unipolar mood disorders regardless of T. gondii 
serologic status (P>0.05, data not shown). In seronegative men, CRP remained a risk factor 
for severe major depression (OR 2.4; 95 % CI, 1.1–5.3), dysthymia (OR, 2.8: 95% CI 1.4–
5.8), and double depression (OR, 4.8; 95% CI 1.7–13.7) and was marginally significant for 
broadly-defined major depression (OR, 2.0; 95% CI 1.0–4.3). Our sample contained too few 
T. gondii seropositive men with these mood disorders for reliable estimates, but ORs were of 
similar or greater magnitude as observed in the seronegative men (data not shown). Thus, 
consideration of T. gondii serologic status did not attenuate sex differences in the 
relationship between CRP and mood disorders.
Additional analysis considered potential confounding by rural versus urban residence. In this 
sample, residents of metro areas were less likely to be seropositive for T. gondii than 
residents of non-metro areas (OR 0.7; 95% CI 0.6 –1.0; p<0.05). However, there was still no 
significant association between T. gondii and any of these mood disorders after inclusion of 
urbanization as an independent variable (p>0.05 for fully adjusted models).
The ORs for logistic regression analysis of T. gondii serology and bipolar disorder are 
shown in table 3. There was a significant association between Toxoplasma seropositivity 
and lifetime history of bipolar disorder with mania and depressive episodes (unadjusted OR, 
2.2; 95% CI, 1.2–4.1; p<0.01). This association remained significant after adjusting for age, 
race/ethnicity and gender (p<0.01), as well as the full model which also controlled for 
poverty level, education level, foreign birth, smoking and CRP (p<0.05). The odds ratio was 
similar after urbanization was stepped into the fully adjusted model (adjusted OR 2.3; 95% 
CI 1.1–4.7; p<0.05). Note, the number of persons with bipolar disorder that included mania 
and depressive episodes was small, only 8 in the T. gondii seropositive subgroup. When 
bipolar disorder type I was considered more broadly to include individuals who met criteria 
for a manic episode but not major depression, the OR was not significant (Table 3). Thus, 
inclusion of respondents who met lifetime criteria for mania but not major depression 
reduced the effect size of T. gondii seropositivity. Specifically, of the 68 respondents in this 
broad bipolar I group (Table 3), 27 met criteria for a manic episode but not major 
depression, and only 1 of these 27 was seropositive for T. gondii. Conversely, of the 41 
respondents meeting criteria for both manic and depressive episodes, 8 were seropositive for 
T. gondii. The association between T. gondii seroprevalence and bipolar disorder II could 
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not be assessed because the estimate among T. gondii positives was highly unstable (RSE > 
50%).
Discussion
The main finding in the group studied is that T. gondii antibody is not associated with major 
depression but is associated with bipolar disorder type I in which both manic and depressive 
features were reported. Strengths of the study include a large sample size with clearly 
defined racial and ethnic composition, and appropriate adjustment for confounding 
demographic and other variables including tobacco smoking. Moreover, the sample is 
community-based and not biased by selection of only inpatients for the psychiatric illness 
group (e.g who could have particular nosocomial exposures).
The lack of an association between T. gondii and MDD confirms prior smaller studies (11–
13). In addition, we considered depression as a symptom spectrum to include dysthymia and 
“double depression”, but we still found no relationship between T. gondii and these unipolar 
mood disorders. We also found no relationship between T. gondii antibody serointensity 
(titer) and dysthymia, but we had inadequate statistical power to examine this relationship in 
the other mood disorder outcomes.
Prior studies in this cohort have reported a positive association between CRP and depression 
in men but not women (20, 21). Our studies expanded these findings to include respondents 
with a history of dysthymia superimposed on major depression (double depression), and 
likewise found a strong association between CRP and this mood disorder in men. We 
considered that this sex difference could involve enhanced or prolonged inflammatory 
responses to T. gondii infection in men. However, we found no evidence to support this 
hypothesis since high CRP was associated with unipolar mood disorders even in T. gondii 
seronegative men. Thus, we found no evidence for a role for T. gondii in unipolar 
depression.
In contrast, T. gondii antibody was associated with bipolar disorder type I. Respondents with 
a prior T. gondii infection (as measured by T. gondii antibody) were approximately 2.3 fold 
more likely to have a history of bipolar disorder type I with manic and depressive symptoms 
than respondents who tested negative for T. gondii antibody. However, this association was 
attenuated when we broadened our definition of bipolar disorder type I to include 
respondents with a history of mania but not major depression. One possible explanation for 
this is that, in individuals predisposed to bipolar disorder type I, infection with T. gondii 
precipitates or accelerates the switch to depression.
There are several limitations to this study. A positive serology result for T. gondii IgG 
indicates that the infection occurred in the past, which could be weeks, months or decades 
prior to the NHANES examination. Thus this study, like prior studies of T. gondii in mood 
disorders, did not examine seroconversion prospectively, though a positive IgG serology is 
thought to be indicative of chronic infection (2). The apparent positive association with T. 
gondii and bipolar disorder type I could be due to greater exposure to the parasite as result of 
behavioral factors that could be more common among individuals with this mood disorder. 
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Conversely, infection could have been congenital in some cases, and a prior study reported 
indirect evidence for a connection between congenital toxoplasmosis and affective psychosis 
(17). Persons in this sample are young (<=39 years), and the negative findings for unipolar 
mood disorders from this sample cannot rule out a connection between T. gondii and MDD 
that is manifested after a long latency or that selectively affects older adults. It is also 
possible that preexisting MDD decreased behaviors related to T. gondii exposure (i.e. 
consumption of raw meat or outdoor exposure to soil) in some individuals, and that this 
outweighed any positive association between T. gondii and MDD in other individuals.
Although the total sample size in this study is large, the connection between T. gondii and 
bipolar disorder type I should be judged cautiously given the small number of respondents 
with both bipolar disorder type I and positive serology for T. gondii. Besides congenital 
infection, there are several mechanisms by which T. gondii could be related to bipolar 
disorder type I. T. gondii evolved to manipulate rodent behavior, and this infection can 
modulate the function of neurotransmitters including serotonin, dopamine and glutamate, all 
of which are involved in bipolar disorders (4, 7, 30). Interestingly, the mood stabilizer 
valproate inhibits replication of T. gondii (31), and treatment of rats with valproate or 
haloperidol reduces some behavioral traits associated with infection, possibly through 
decreasing T. gondii replication or neuroinvasiveness (32). Infection with T. gondii could 
also exacerbate neurocircuitry changes caused by genetic susceptibility to bipolar disorder. 
For example, during neuroinvasion or reactivation T. gondii could disrupt neural cell 
adhesion, which could be vulnerable to perturbation due to host genetic variants (33, 34). 
Genetic variants causing a predisposition to bipolar disorder could also interact with T. 
gondii infection by modifying the neurodistribution, neuroinvasiveness, or transition to 
tissue cysts of the parasite, and therefore confer adverse effects of infection on only a subset 
of individuals. For example, the major histocompatability region (MHC) on chromosome 6 
harbors risk alleles for both bipolar disorder and schizophrenia (35), and MHC II (HLA-DQ 
allele) is linked with parasite burden in the brain and neurological outcome in congenitally 
T. gondii-infected infants and immunosuppressed adults (36, 37).
In conclusion, given that most studies have found a connection between T. gondii and 
schizophrenia, our finding that T. gondii is not associated with unipolar depression but might 
be associated with a subtype of bipolar disorder is indirect evidence that bipolar disorder and 
schizophrenia may share at least some etiological pathways.
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Table 1
Sociodemographic and health-related variables in the NHANES III in our analytic samplea

























































T. gondii antibody titers
(T. gondii serology)
Negative (< 6 IU)
Positive (>=6 IU)
High titer (>=240 IU)
















Analytic sample consisted of individuals age 15–39 years who were interviewed, examined, had serologic testing to T. gondii and complete mood 
disorder data (N=7440).
b
Number of respondents may not add to the total sample due to missing data for some variables.
c
- Weighted percent of U.S. population as described in methods.
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Table 2










































































































































Model 1 was adjusted for age, race/ethnicity, and sex. Model 2 was adjusted for age, race/ethnicity, sex, poverty level, education level, foreign 
birth, current smoking and CRP level.
a
-Negative, < 6 IU; Positive >=6 IU.
b
-Weighted percent of U.S. population meeting mood disorder criteria.
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